GeneDx receives FDA Breakthrough Device Designation for whole genome and exome testsByMorgan Ebert, Managing EditorNovember 10th 2025
Safety, tolerability of tenapanor in pediatric IBS-C patients, with Thomas Wallach, MDByThomas Wallach, MDNovember 7th 2025
Odevixibat demonstrates sustained pruritus and bile acid improvements in FIC1 deficiencyByJoshua Fitch, Senior Editor November 7th 2025
Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-CByJulie Khlevner, MD, AGAFNovember 7th 2025